AR088748A1 - Macrociclos como inhibidores del factor xia - Google Patents
Macrociclos como inhibidores del factor xiaInfo
- Publication number
- AR088748A1 AR088748A1 ARP120102878A ARP120102878A AR088748A1 AR 088748 A1 AR088748 A1 AR 088748A1 AR P120102878 A ARP120102878 A AR P120102878A AR P120102878 A ARP120102878 A AR P120102878A AR 088748 A1 AR088748 A1 AR 088748A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycle
- halogen
- nhc
- carbon atoms
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 26
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Estos compuestos son inhibidores selectivos del factor Xla o inhibidores duales de FXIa y calicreína plasmática. También composiciones farmacéuticas que comprenden estos compuestos y métodos para tratar trastornos tromboembólicos y/o inflamatorios mediante su uso. Reivindicación 1: Un compuesto de la fórmula (1), o un estereoisómero, un tautómero, una sal aceptable desde el punto de vista farmacéutico, un solvato de este caracterizado porque: el anillo A se selecciona de arilo y un heterociclo de 5- a 6- miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NH, N(alquilo C₁₋₄), S(O)ₚ y O, en donde el arilo y el heterociclo se sustituyen con R¹; el anillo B es un heterociclo de 5- a 6- miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NH, S(O)ₚ y O, en donde el heterociclo se sustituye opcionalmente con R¹⁰; el anillo C es un heterociclo de 4- a 5- miembros que comprende: átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NR⁹, S(O)ₚ y O, en donde el heterociclo se sustituye opcionalmente con R²; X¹ se selecciona de alquileno C₁₋₄ y alquenileno C₂₋₄; opcionalmente, uno o más de los átomos de carbono del alquileno y alquenileno se pueden reemplazar por O, S(O)ₚ, NH y N(alquilo C₁₋₄); R¹, se selecciona, independientemente en cada caso, de H, halógeno, NO₂, alquilo C₁₋₆, OH, OMe y CN; R² se selecciona de H, =O, OH, NH₂, CF₃, halógeno y alquilo C₁₋₄ opcionalmente sustituido con OH; R³ se selecciona de H y alquilo C₁₋₄; alternativamente, R² y R³, junto con los átomos a los que se unen directa o indirectamente, forman un anillo que se sustituye opcionalmente con =O; R⁴ se selecciona de H, alquilo C₁₋₄, hidroxilo y cicloalquilo C₃₋₆; R⁵ se selecciona de H y alquilo C₁₋₄; R⁶ se selecciona de H, halógeno, C(O)OH y C(O)O(alquilo C₁₋₄); R⁷ se selecciona del grupo que consiste en: H, alquilo C₁₋₄ y CF₃; de manera alternativa, R⁶ y R⁷ son, en forma conjunta, =O; R⁸, se selecciona, independientemente en cada caso, de H, halógeno, NHC(O)O-alquilo C₁₋₄, CN, OH, O-alquilo C₁₋₄; CF₃, CO₂H, CO₂(alquilo C₁₋₄), -CH₂CO₂H, -(CH₂)₂CO₂H, -CH₂CO₂(alquilo C₁₋₄), -(CH₂)₂CO₂(alquilo C₁₋₄), NH₂, -CH₂NH₂, -NHCO(alquilo C₁₋₄), -NHCO₂(CH₂)₁₋₂O(alquilo C₁₋₄), -NHCO₂(CH₂)₁₋₃O(alquilo C₁₋₄), NHCO₂CH₂CH(C₁₋₄ alquil)O(alquilo C₁₋₄), -NHCO₂(CH₂)₁₋₂OH, -NHCO₂CH₂CO₂H, -CH₂NHCO₂(alquilo C₁₋₄), -NHC(O)NH(alquilo C₁₋₄), -NHC(O)N(alquilo C₁₋₄)₂, NHC(O)NH(C₁₋₄ alquil)N[heterociclo de 5- a 6- miembros)], -NHSO₂(alquilo C₁₋₄), -CONH₂, -CONH(alquilo C₁₋₄), -CON(alquilo C₁₋₄)₂ y -CH₂CONH₂; R⁹ se selecciona de H y alquilo C₁₋₄; R¹⁰, se selecciona, independientemente en cada caso, de H, halógeno, CN, =O, OH, NH₂, cicloalquilo C₃₋₆, alcoxi C₁₋₄, CF₃, CH₂OH, CO₂H, CO₂(alquilo C₁₋₄) y CONH; y p se selecciona, independientemente en cada caso, de 0, 1 y 2; siempre que los compuestos de fórmula (2) y (3) estén excluidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515401P | 2011-08-05 | 2011-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088748A1 true AR088748A1 (es) | 2014-07-02 |
Family
ID=46889416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102878A AR088748A1 (es) | 2011-08-05 | 2012-08-07 | Macrociclos como inhibidores del factor xia |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9221818B2 (es) |
| EP (1) | EP2739628B1 (es) |
| JP (1) | JP6158181B2 (es) |
| CN (1) | CN103857681B (es) |
| AR (1) | AR088748A1 (es) |
| BR (1) | BR112014002202A2 (es) |
| CA (1) | CA2844254A1 (es) |
| CY (1) | CY1119281T1 (es) |
| DK (1) | DK2739628T3 (es) |
| EA (1) | EA024791B1 (es) |
| ES (1) | ES2635088T3 (es) |
| HR (1) | HRP20171122T1 (es) |
| HU (1) | HUE034487T2 (es) |
| LT (1) | LT2739628T (es) |
| MX (1) | MX345763B (es) |
| PL (1) | PL2739628T3 (es) |
| PT (1) | PT2739628T (es) |
| RS (1) | RS56244B1 (es) |
| SI (1) | SI2739628T1 (es) |
| SM (1) | SMT201700413T1 (es) |
| TW (1) | TW201311689A (es) |
| WO (1) | WO2013022818A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602266A (en) | 2010-02-11 | 2014-05-30 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6033319B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| WO2013055984A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| AU2013296259A1 (en) * | 2012-08-03 | 2015-03-19 | Bristol-Myers Squibb Company | Dihydropyridone P1 as factor XIa inhibitors |
| US9376444B2 (en) | 2012-08-03 | 2016-06-28 | Bristol-Myers Squibb Company | Dihydropyridone P1 as factor XIa inhibitors |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| FR3010076B1 (fr) * | 2013-09-02 | 2016-12-23 | Centre Nat De La Rech Scient - Cnrs - | Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques |
| NO2760821T3 (es) | 2014-01-31 | 2018-03-10 | ||
| SG10201908467RA (en) * | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| WO2015123093A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| WO2015123091A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3134408B1 (en) | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| NO2721243T3 (es) * | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| ES2762987T3 (es) * | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| JP6629958B2 (ja) | 2015-07-29 | 2020-01-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 |
| CN114874222B (zh) | 2015-07-29 | 2025-06-06 | 百时美施贵宝公司 | 携带非芳族p2,基团的因子xia新大环 |
| DK4019022T3 (en) | 2015-10-01 | 2024-02-19 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| EP3368036B1 (en) | 2015-10-29 | 2022-07-20 | Merck Sharp & Dohme LLC | Macrocyclic pyridine-n-oxide derivatives as factor xia inhibitors |
| KR20180117156A (ko) | 2016-03-02 | 2018-10-26 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클 |
| EP3455211A1 (en) * | 2016-05-10 | 2019-03-20 | Solvay SA | Composition comprising 3-(haloalkyl or formyl)-1h-pyrazole-4-carboxylic acids or esters, its manufacture and its use for the preparation of carboxamides |
| WO2018039094A1 (en) | 2016-08-22 | 2018-03-01 | Merck Sharp & Dohme Corp. | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| EP3309143A1 (en) * | 2016-10-17 | 2018-04-18 | Solvay SA | Method for producing fluoroformate compounds |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN107011275A (zh) * | 2017-03-31 | 2017-08-04 | 深圳市众康动保科技有限公司 | 一种1,4,5‑三取代‑1,2,3‑三氮唑类化合物的合成方法 |
| WO2019011166A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 大环酰胺化合物及其药物组合物和用途 |
| WO2020211781A1 (zh) | 2019-04-16 | 2020-10-22 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CN114008047B (zh) | 2019-07-23 | 2023-03-21 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| EP4146205A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS |
| IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| CN112920005B (zh) * | 2021-01-31 | 2022-06-14 | 上海李氏化学科技有限公司 | 一种(r)-3-(3-氯-2-氟苯)-4,5-二氢异噁唑-5-羧酸的制备方法 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| TW202309052A (zh) * | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CN113336715B (zh) * | 2021-08-04 | 2021-11-23 | 山东海利尔化工有限公司 | 一种含二氧戊环的三唑类化合物及其中间体的制备方法 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AU2002322802A1 (en) | 2001-07-27 | 2003-02-17 | Merck And Co., Inc. | Thrombin inhibitors |
| CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| EP1841504B1 (en) | 2005-01-13 | 2014-11-19 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| EP1966141A1 (en) * | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| NZ568595A (en) | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
| WO2007070816A2 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| PE20071132A1 (es) | 2005-12-23 | 2007-12-14 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| US20080099168A1 (en) | 2006-10-26 | 2008-05-01 | Kou-Chang Liu | Soft and absorbent tissue products |
| EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| NZ602266A (en) | 2010-02-11 | 2014-05-30 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6033319B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| WO2013055984A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9376444B2 (en) | 2012-08-03 | 2016-06-28 | Bristol-Myers Squibb Company | Dihydropyridone P1 as factor XIa inhibitors |
| AU2013296259A1 (en) | 2012-08-03 | 2015-03-19 | Bristol-Myers Squibb Company | Dihydropyridone P1 as factor XIa inhibitors |
| TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Bristol Myers Squibb Co | Bir faktör XIa inhibitörünün kristalli formları. |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
-
2012
- 2012-08-03 TW TW101128173A patent/TW201311689A/zh unknown
- 2012-08-06 HU HUE12762427A patent/HUE034487T2/en unknown
- 2012-08-06 HR HRP20171122TT patent/HRP20171122T1/hr unknown
- 2012-08-06 SM SM20170413T patent/SMT201700413T1/it unknown
- 2012-08-06 WO PCT/US2012/049706 patent/WO2013022818A1/en not_active Ceased
- 2012-08-06 RS RS20170852A patent/RS56244B1/sr unknown
- 2012-08-06 SI SI201231004T patent/SI2739628T1/sl unknown
- 2012-08-06 PT PT127624278T patent/PT2739628T/pt unknown
- 2012-08-06 PL PL12762427T patent/PL2739628T3/pl unknown
- 2012-08-06 CA CA2844254A patent/CA2844254A1/en not_active Abandoned
- 2012-08-06 CN CN201280049108.9A patent/CN103857681B/zh active Active
- 2012-08-06 LT LTEP12762427.8T patent/LT2739628T/lt unknown
- 2012-08-06 EA EA201490418A patent/EA024791B1/ru not_active IP Right Cessation
- 2012-08-06 DK DK12762427.8T patent/DK2739628T3/en active
- 2012-08-06 EP EP12762427.8A patent/EP2739628B1/en active Active
- 2012-08-06 BR BR112014002202A patent/BR112014002202A2/pt not_active Application Discontinuation
- 2012-08-06 ES ES12762427.8T patent/ES2635088T3/es active Active
- 2012-08-06 JP JP2014524152A patent/JP6158181B2/ja active Active
- 2012-08-06 MX MX2014000831A patent/MX345763B/es active IP Right Grant
- 2012-08-06 US US14/236,973 patent/US9221818B2/en active Active
- 2012-08-07 AR ARP120102878A patent/AR088748A1/es unknown
-
2015
- 2015-11-16 US US14/942,013 patent/US9611274B2/en active Active
-
2017
- 2017-02-21 US US15/437,605 patent/US9902742B2/en active Active
- 2017-09-04 CY CY20171100930T patent/CY1119281T1/el unknown
-
2018
- 2018-01-25 US US15/879,619 patent/US10208068B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140221338A1 (en) | 2014-08-07 |
| BR112014002202A2 (pt) | 2017-03-07 |
| MX2014000831A (es) | 2014-02-27 |
| DK2739628T3 (en) | 2017-09-11 |
| HUE034487T2 (en) | 2018-02-28 |
| SMT201700413T1 (it) | 2017-11-15 |
| EA201490418A1 (ru) | 2014-05-30 |
| CN103857681B (zh) | 2017-07-14 |
| US9611274B2 (en) | 2017-04-04 |
| EP2739628B1 (en) | 2017-06-07 |
| JP6158181B2 (ja) | 2017-07-05 |
| US9902742B2 (en) | 2018-02-27 |
| MX345763B (es) | 2017-02-15 |
| EP2739628A1 (en) | 2014-06-11 |
| US20160068544A1 (en) | 2016-03-10 |
| CA2844254A1 (en) | 2013-02-14 |
| PT2739628T (pt) | 2017-08-02 |
| CY1119281T1 (el) | 2018-02-14 |
| ES2635088T3 (es) | 2017-10-02 |
| PL2739628T3 (pl) | 2017-11-30 |
| US10208068B2 (en) | 2019-02-19 |
| US20180148461A1 (en) | 2018-05-31 |
| US20170158712A1 (en) | 2017-06-08 |
| WO2013022818A1 (en) | 2013-02-14 |
| US9221818B2 (en) | 2015-12-29 |
| RS56244B1 (sr) | 2017-11-30 |
| TW201311689A (zh) | 2013-03-16 |
| LT2739628T (lt) | 2017-08-25 |
| SI2739628T1 (sl) | 2017-08-31 |
| JP2014521701A (ja) | 2014-08-28 |
| EA024791B1 (ru) | 2016-10-31 |
| HRP20171122T1 (hr) | 2017-10-06 |
| CN103857681A (zh) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR101208A1 (es) | Espirocicloheptanos como inhibidores de rock | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR123848A1 (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| AR089207A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |